Compare

Financière de Tubize SA/€TUB

1D1W1M3M6MYTD1Y5YMAX

About Financière de Tubize SA

Financière de Tubize SA is a Belgian holding company established in 1928, serving as the reference shareholder of UCB, a global biopharmaceutical company. Its sole investment is a significant stake in UCB, focusing on long-term value creation through active participation in UCB's strategic decisions. Headquartered in Brussels, Belgium, the company embodies strong family and entrepreneurial values, uniting descendants of UCB's founder, Emmanuel Janssen, and like-minded investors. This strategic positioning provides UCB with the stability necessary for sustained growth and investment in new products for patients with serious illnesses.
Ticker
€TUB
Sector
Health
Primary listing
BSE
Employees
3
Headquarters
Brussels, Belgium
Website
www.financiere-tubize.be

TUB Metrics

BasicAdvanced
€9.7B
98.92
€2.21
0.39
€0.76
0.35%

Bulls say / Bears say

UCB’s 22 October guidance upgrade points to strong near-term momentum: it now expects 2026 revenue growth in the low twenties and adjusted EBITDA growth in the low-to-mid forties at constant exchange rates, driven by Bimzelx and Cimzia. (UCB)
UCB’s growth is not resting on one launch alone: first-half revenue rose 22% and adjusted EBITDA 68%, while Bimzelx sales nearly doubled and the company raised its peak-sales ambition to at least €7 billion. Other growth medicines and pipeline additions could extend that momentum. (UCB)
Tubize’s first-half profit rose 5.4%, supported by a 4.3% increase in the UCB dividend it received; its own shareholder dividend also rose 3.8%. It modestly increased its UCB holding, giving investors growing cash distributions and exposure to further gains in its core asset. (Financière de Tubize SA)
Tubize is a single-asset holding, so its earnings and cash flows depend heavily on UCB’s performance and dividend policy. Its half-year report recorded €102.3 million of UCB dividends received against €100.8 million of profit, underscoring that dependence. (Financière de Tubize SA)
Tubize’s valuation leaves little room for disappointment: a recent analysis put its price-to-earnings ratio at about 83.7 times, well above the pharmaceutical sector’s roughly 21.2 times. A pullback in UCB or a weaker outlook could therefore expose the shares to a sharp valuation reset. (Yahoo Finance)
UCB faces ongoing generic pressure on older medicines: Briviact lost US exclusivity in February 2026, while VIMPAT sales in Japan have been affected by generics. That erosion could offset part of the growth from newer products held indirectly by Tubize. (UCB)
Data summarised monthly by Lightyear AI. Last updated on 22 Oct 2026.

TUB Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Funds containing TUB

AllEURUSDGBP
Funds
Fund name
Fund size
€TUB weighting
iShares STOXX Europe 600 Health Care€EXV4
€709M0.27%
iShares MSCI Europe Health Care Sector£ESIH
€890M0.26%
iShares MSCI Europe Health Care Sector€ESIH
€890M0.26%
Invesco MSCI World Equal Weight£MWEP
$2B0.09%
Invesco MSCI World Equal Weight$MWEQ
$2B0.09%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.